A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's disease
HAV Vaccines Limited funded the trial and acted as trial sponsor. The Sponsor was involved in protocol development, trial conduct, including data monitoring and analysis, and the preparation of this manuscript in line with the Medicines for Human Use (Clinical Trials) Regulations 2004 and amendments.
Authors
- Emma Gray (ORCID: https://orcid.org/0009-0008-6542-6535)
- Michael Stallibrass
- Jeremy Sanderson (ORCID: https://orcid.org/0000-0002-0556-6965)
- Katerina Rapi
- Katie Ewer (ORCID: https://orcid.org/0000-0001-9827-9836)
- Alison M. Lawrie
- Lisa Stockdale (ORCID: https://orcid.org/0000-0002-2576-8783)
- Rebecca Makinson (ORCID: https://orcid.org/0000-0001-7582-9073)
- Sarah C. Gilbert (ORCID: https://orcid.org/0000-0002-6823-9750)
- Rayka Malek (ORCID: https://orcid.org/0000-0001-5231-3648)
- Lindsey West (ORCID: https://orcid.org/0000-0002-4065-4186)
- Samuel Provstgaard-Morys
- Abdel Douiri (ORCID: https://orcid.org/0000-0002-4354-4433)
- Fatima El Oulidi
- Isabelle Lanigan
- Jeremy Aboagye
- Nishat Halim
- Adrian V S Hill
- Emily Greenlay
- Paul Ian Cross
Institutions
- King's College - North Carolina (US)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Schunk (United Kingdom) (GB)
- Minnesota Wire (United States) (US)
- Jenner Institute (GB)
Publication Details
- Journal
- EBioMedicine
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1016/j.ebiom.2025.105570
- Citations
- 3
- Primary Topic
- Mycobacterium research and diagnosis
- Type
- article
- Field-Weighted Citation Impact
- 4.06